Ocular Therapeutix (OCUL) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 1.3% versus a loss of 36.9%. Zenas BioPharma is the larger company by market cap ($1.74 billion vs $1.66 billion), about 1.0 times the size. Ocular Therapeutix converts more of its revenue into profit, with a net margin of -511.9% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | ZBIO |
|---|---|---|
| Share price | $7.56 | $26.63 |
| Market cap | $1.66B | $1.74B |
| 1-day change | +0.60% | +1.49% |
| YTD return | -38.14% | -27.73% |
| 1-year return | -36.94% | +1.31% |
| 5-year return | -32.89% | — |
| EPS (TTM) | $-1.40 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $51.95M | $10.00M |
| Revenue growth (YoY) | -18.47% | +100.00% |
| Net income (latest FY) | $-265.94M | $-377.74M |
| Gross margin | 87.35% | — |
| Operating margin | -519.75% | -3830.57% |
| Net margin | -511.90% | -3777.37% |
| 52-week high | $16.44 | $44.60 |
| 52-week low | $6.23 | $13.50 |
| Distance from 52-week high | -54.05% | -40.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +258.57% | +79.80% |
| Average volume | 2.80M | 733.34K |
| Shares outstanding | 219.62M | 65.18M |
| Employees | 325 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed OCUL by 38.3 percentage points over the past year.
- Ocular Therapeutix is more profitable, keeping -511.9 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs -18.47%).
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
OCUL vs ZBIO FAQ
Which is bigger, Ocular Therapeutix or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.74B compared with $1.66B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, OCUL or ZBIO?
ZBIO returned +1.31% over the past 12 months, compared with -36.94% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.